FVB(Cg)-Tg(Ins2-CALM1)26Ove Tg(Cryaa-TAg)1Ove/PneJ

Transgenic mice contain a construct in which a chicken calmodulin minigene (CALM1) is driven by the rat insulin II promoter (Ins2). In addition, these mice express a truncated SV40 T antigen (TAg) controlled by a lens specific alpha A crystallin (Cryaa) promoter. The transgenes have been shown to co-segregate. Publications show that FVB-Ove26 transgenic mice are viable, display small eyes with cataracts and are hyperglycemic within 24 hours of age. S1 Nuclease protection assays indicate expression of calmodulin in the pancreas of 40-60 day old transgenic mice. Immunofluorescence analysis indicates increased levels of camodulin only in pancreatic beta cells. Digital image scanning indicated the concentration of camodulin in transgenic beta cells is 5-fold higher than in wild type controls. Pancreatic insulin was 28% of control levels by 15 days of age. Insulin mRNA levels were also reduced in the transgenic animals. Transgenic mice experience hypoalbuminemia, elevated blood pressure, impaired cardiomyocytes and late stage diabetic nephropathy (Zheng et al. 2004). Although transgenic mice are hyperglycemic within 24 hours of age, they are able to survive over a year without insulin treatment. Phenotyping of this stock at The Jackson Laboratory confirmed the published values for diabetes-related phenotypes, but failed to confirm diabetic nephropathy at the 6 month study endpoint. Similarly, glomerular filtration rates were not decreased versus non-transgenic controls at a 9-month sampling.


Phenotyped ForOther Resources
Histology
Images
ReagentsPublications
Data AvailableData AvailableData AvailableNo DataNo DataNo Data   


Data (.csv filetype)

plasma glucose (mg/dL)

SeriesSexNAvgSD
FVB(Cg)-Tg(Ins2-CALM1)26Ove Tg(Cryaa-TAg)1Ove/PneJBoth19707.79171.57
 Female9786.44116.39
 Male10637.00182.10
Avg = 707.79
Std = 171.57
N = 19

insulin, plasma (pg/ml)

SeriesSexNAvgSD
FVB(Cg)-Tg(Ins2-CALM1)26Ove Tg(Cryaa-TAg)1Ove/PneJBoth18283.33188.15
 Female8365.00113.86
 Male10218.00209.16
Avg = 283.33
Std = 188.15
N = 18

W rodent (g)

SeriesSexNAvgSD
FVB(Cg)-Tg(Ins2-CALM1)26Ove Tg(Cryaa-TAg)1Ove/PneJBoth7122.301.84
 Female1222.032.93
 Male5922.361.52
Avg = 23.8
Std = 1.63
N = 14
Age = 26 Avg = 23.98
Std = 0.95
N = 4
Age = 24 Avg = 23.72
Std = 1.23
N = 4
Age = 22 Avg = 22.83
Std = 0.87
N = 4
Age = 20 Avg = 23.02
Std = 1.47
N = 5
Age = 18 Avg = 22.45
Std = 0.98
N = 6
Age = 16 Avg = 22.05
Std = 0.77
N = 6
Age = 14 Avg = 21.01
Std = 0.72
N = 7
Age = 12 Avg = 21.3
Std = 1.63
N = 7
Age = 10 Avg = 21.27
Std = 0.74
N = 6
Age = 8 Avg = 21
Std = 0.9
N = 7
Age = 6 Avg = 15.4
Std = 0
N = 1
Age = 4 Avg = 23.8
Std = 1.63
N = 14
Age = 26 Avg = 23.98
Std = 0.95
N = 4
Age = 24 Avg = 23.72
Std = 1.23
N = 4
Age = 22 Avg = 22.83
Std = 0.87
N = 4
Age = 20 Avg = 23.02
Std = 1.47
N = 5
Age = 18 Avg = 22.45
Std = 0.98
N = 6
Age = 16 Avg = 22.05
Std = 0.77
N = 6
Age = 14 Avg = 21.01
Std = 0.72
N = 7
Age = 12 Avg = 21.3
Std = 1.63
N = 7
Age = 10 Avg = 21.27
Std = 0.74
N = 6
Age = 8 Avg = 21
Std = 0.9
N = 7
Age = 6 Avg = 15.4
Std = 0
N = 1
Age = 4






Cardiovascular Validation
AALA (µm²)plasma glucose (mg/dL)insulin, plasma (pg/ml)
No Data707.79283.33